# Pasi A. Jänne

Source: https://onco.cc/people/pasi-janne/  
OnCo record `pasi-janne` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Co-discovered EGFR mutations in lung cancer and has led the drug development that followed, from osimertinib to KRAS G12C inhibitors.

## Summary

Pasi A. Jänne is Director of the Lowe Center for Thoracic Oncology and the Belfer Center for Applied Cancer Science at Dana-Farber Brigham Cancer Center. He is known for co-discovering in 2004 that EGFR mutations predict response to gefitinib in lung cancer, and for leading the drug development that followed, including FLAURA2 with osimertinib plus chemotherapy and the KRYSTAL-1 adagrasib lung study. His selected papers cover the activating EGFR mutations underlying gefitinib responsiveness, adagrasib in KRAS G12C-mutant lung cancer, and osimertinib with or without chemotherapy in EGFR-mutated lung cancer. He directs Dana-Farber's thoracic oncology centre and studies targeted therapy resistance.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Lowe Center for Thoracic Oncology; Director, Belfer Center for Applied Cancer Science
- Specialisms: EGFR-mutant lung cancer; Targeted therapy resistance; KRAS G12C

## Sources

- Dana-Farber profile: https://www.dana-farber.org/find-a-doctor/pasi-a-janne
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Janne%20PA%5BAuthor%5D

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [HER2-mutant non-small-cell lung cancer](https://onco.cc/cancers/her2-mutant-nsclc/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [KRAS](https://onco.cc/targets/kras/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/), [Osimertinib](https://onco.cc/drugs/osimertinib/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/), [International Association for the Study of Lung Cancer](https://onco.cc/institutions/iaslc/)
- trials: [FLAURA2](https://onco.cc/trials/flaura2/)
- key papers: [Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib](https://onco.cc/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/), [EGFR mutation and resistance of non-small-cell lung cancer to gefitinib](https://onco.cc/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/), [EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy](https://onco.cc/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/), [FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer](https://onco.cc/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/), [MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling](https://onco.cc/key-papers/paper-engelman-met-amplification-gefitinib-resistance-science-2007/), [MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression](https://onco.cc/key-papers/paper-awad-met-exon-14-mutations-lung-jco-2016/), [Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC](https://onco.cc/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/)

---
JSON: https://onco.cc/api/v1/entities/pasi-janne.json